

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, JUNE 28, 2024

Reference is made to the circular (the “Circular”) of SciClone Pharmaceuticals (Holdings) Limited (the “Company”) incorporating, amongst others, the notice (the “Notice”) of the annual general meeting of the Company (the “AGM”), dated April 30, 2024. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE AGM

At the AGM held on Friday, June 28, 2024, all the proposed resolutions as set out in the Notice were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements and the reports of the directors and auditors for the year ended December 31, 2023.	121,135,792 (97.59%)	2,988,000 (2.41%)
2(a).	To re-elect Ms. Pan Rongrong as an executive director of the Company.	117,103,511 (94.34%)	7,020,281 (5.66%)
2(b).	To re-elect Dr. Daniel Luzius Vasella as a non-executive director of the Company.	114,246,611 (92.04%)	9,877,181 (7.96%)
2(c).	To re-elect Ms. Wang Haixia as a non-executive director of the Company.	N/A ^{Note(j)}	N/A ^{Note(j)}
2(d).	To re-elect Dr. Liu Guoen as an independent non-executive director of the Company.	122,460,017 (98.66%)	1,663,775 (1.34%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
2(e).	To authorize the board of directors to fix the respective directors' remuneration.	123,966,632 (99.87%)	157,160 (0.13%)
3.	To re-appoint PricewaterhouseCoopers as the auditor and to authorize the board of directors to fix its remuneration.	123,192,292 (99.25%)	931,500 (0.75%)
4.	To give a general mandate to the directors to repurchase shares of the Company not exceeding 10% of total number of issued shares of the Company as at the date of passing of this resolution.	121,957,292 (98.25%)	2,166,500 (1.75%)
5.	To give a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	54,133,905 (43.61%)	69,989,887 (56.39%)
6.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	54,217,312 (43.68%)	69,906,480 (56.32%)
Special Resolution		Number of Votes (%)	
		For	Against
7.	To approve the proposed amendments to the existing amended and restated articles of association of the Company and to adopt the third amended and restated articles of association of the Company in substitution for and to the exclusion of the existing amended and restated articles of association of the Company, as set out in the notice convening the AGM dated April 30, 2024.	124,116,792 (99.99%)	7,000 (0.01%)

Notes:

- (a) As a majority of the votes were cast in favour of each of the ordinary resolutions numbered 1 to 4 (except the resolution numbered 2(c)), such resolutions were duly passed as ordinary resolutions.

As less than 50% of votes were cast in favour of each of the ordinary resolutions numbered 5 to 6, such resolutions were not passed.

- (b) As more than three-fourths of the votes were cast in favour of the special resolution numbered 7, the resolution was duly passed as a special resolution.

- (c) As at the date of the AGM, the total number of shares of the Company in issue was 630,826,562 shares.
- (d) The trustee of the Post-IPO RSU Plan of the Company, which held 3,384,023 shares as at the date of this announcement, was required to and had abstained from voting on the resolutions proposed at the AGM under Rule 17.05A of the Listing Rules. Accordingly, the total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 627,442,539 shares.
- (e) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (f) Save as disclosed, none of the shareholders of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM.
- (g) None of the shareholders of the Company have stated their intention in the Company’s circular dated April 30, 2024 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (h) The Company’s branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (i) All directors of the Company attended the AGM.
- (j) Reference is made to the announcement of the Company dated June 26, 2024, pursuant to which the Company announced that Ms. Wang Haixia would retire from office at the AGM and did not offer herself for re-election at the AGM (the “**Retirement**”). Due to the Retirement, Ms. Wang Haixia retired as a non-executive Director at the AGM and the above resolution No. 2(c) was no longer applicable and was not put forward for consideration at the AGM.

By Order of the Board
SciClone Pharmaceuticals (Holdings) Limited
ZHAO Hong
Executive Director, Chief Executive Officer and President

Hong Kong, June 28, 2024

As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella and Ms. Lin Shirley Yi-Hsien as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *For identification purpose only*